3,556 Shares in Insulet Corporation $PODD Acquired by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, Holdings Channel reports. The firm purchased 3,556 shares of the medical instruments supplier’s stock, valued at approximately $541,000.

A number of other large investors also recently modified their holdings of PODD. Larson Financial Group LLC lifted its position in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in Insulet in the fourth quarter valued at $26,000. Elyxium Wealth LLC acquired a new stake in Insulet in the fourth quarter valued at $28,000. DV Equities LLC acquired a new stake in Insulet in the fourth quarter valued at $28,000. Finally, MV Capital Management Inc. purchased a new stake in Insulet during the 4th quarter worth about $29,000.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.36% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Robert W. Baird set a $175.00 price objective on Insulet in a research report on Thursday, August 6th. Truist Financial restated a “hold” rating and set a $153.00 target price (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Wall Street Zen downgraded Insulet from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 9th. Barclays dropped their price target on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Finally, Jefferies Financial Group cut their price objective on shares of Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $195.40.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: CEO Ashley McEvoy purchased 1,100 Insulet shares at an average price of $147.47, an investment of approximately $162,200. The transaction increased her direct holdings by about 5% and may signal management confidence after the stock’s substantial decline. Insulet CEO share purchase article
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Levi & Korsinsky, and others—are soliciting investors who purchased PODD securities during periods generally spanning February 21, 2025, through May 26, 2026. Investors have until August 31, 2026, to seek appointment as lead plaintiff. These announcements largely repeat existing litigation information rather than represent new operating developments. Rosen Law Firm Insulet deadline article
• Negative Sentiment: The lawsuit-related releases allege that Insulet and certain officers violated federal securities laws by failing to disclose issues associated with two voluntary Medical Device Corrections involving Omnipod insulin-delivery systems. The allegations reportedly concern systemic manufacturing defects and potential investor losses; they have not been proven in court. Continued legal publicity increases regulatory, financial, and reputational uncertainty for Insulet and is likely the main reason investor sentiment remains weak. Levi and Korsinsky Insulet class action article

Insulet Trading Down 1.8%

PODD opened at $145.42 on Tuesday. The firm has a market cap of $10.08 billion, a price-to-earnings ratio of 27.18, a price-to-earnings-growth ratio of 1.17 and a beta of 1.10. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The business’s 50 day moving average is $154.61 and its two-hundred day moving average is $183.56. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts predict that Insulet Corporation will post 6.51 EPS for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.